UK-based pharmaceutical firm GlaxoSmithKline has sealed a deal to buy Human Genome Sciences for $3.6bn.
GlaxoSmithKline originally offered $13 a share in April but have now raised this to an accepted $14.25 a share – bringing the purchase to $3.6bn (£2.3bn). As a result of the takeover GSK will gain control of an immune system drug called Benlysta that it previously co-owned with US biotechnology firm Human Genome Sciences (HGS).…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
